ERBB2 and neoplasm: After screening 1745 patients according to the inclusion and exclusion criteria described above, we excluded 136 HER-2 positive patients, 169 patients who could not tolerate chemotherapy or immunotherapy, 179 patients who had severe systemic or autoimmune disease, 248 patients with multiple primary tumors or with unknown primary tumor sites, 123 patients without complete clinical data, and 118 patients without evaluable lesions for efficacy.